Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Glenmark Pharmaceuticals
GLENMARK
Glenmark Pharmaceuticals
Global Regulatory Burdens Will Hamper Legacy Generic Business
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
13 Jul 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹1,500.00
28.3% overvalued
intrinsic discount
20 Aug
₹1,924.00
Loading
1Y
14.5%
7D
-5.2%
Author's Valuation
₹1.5k
28.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹1.5k
28.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-10b
183b
2014
2017
2020
2023
2025
2026
2028
Revenue ₹183.4b
Earnings ₹29.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.41%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹29.08b
Earnings '28
x
25.49x
PE Ratio '28
=
₹741.32b
Market Cap '28
₹741.32b
Market Cap '28
/
345.90m
No. shares '28
=
₹2.14k
Share Price '28
₹2.14k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹1.50k
Fair Value '25